1. Introduction {#s0005}
===============

Genomic structural alterations in stem cells have been reported since the first embryonic stem cell lines were developed in primates by [@bb0115] and [@bb0120]. Many other such examples were subsequently reported, including structural abnormalities like 46,X,idic(X)(q21) ([@bb0060]) and 47,XX,del(7)(q11.2),+i(12)(p10) ([@bb0050]), or numerical ones like aneuploidies found in up to 20% of the studied cells ([@bb0090]). Furthermore, CTG repeat instability, variations in copy number, gain and loss of heterozygosity, epigenetic changes and karyotypic instability induced by cell culture conditions in human stem cell lines have been repeatedly described ([@bb0020], [@bb0125], [@bb0005], [@bb0015], [@bb0065], [@bb0080]).

Of special interest among stem cells are induced pluripotent stem cells (iPSC), which add the potential risk aris\\ing from the methods used to derive them from somatic cells to those intrinsic to the manipulation and expansion of any stem cell in vitro. Thus, chromosomal monosomy induced by modified stem cells used in therapy was recently described ([@bb0025]). Similarly, [@bb0045] reported a higher number of copy number variants (CNVs) in iPSC cells at early passages of cell culture, potentially as a result of selection during reprogramming to pluripotency.

Genomic anomalies can be found in any type of pluripotent cell, regardless of culture conditions, manipulation or modifications. However, there is a significant lack of information about genomic instabilities and variations that could potentially be found in differentiated derivatives of pluripotent cell types. If those cells would be used either in cell therapy or as a model in basic research, it is important that their genomic integrity be analyzed and characterized. Intuitively, the idea that such variants could accumulate in the relatively short time spanning the completion of a typical differentiation protocol (1--3 weeks) could be easily dismissed ([@bb0135], [@bb0110]).

Our data, however, indicate that this precisely could be the case. Preliminary evidence was obtained by application of multiplex-fluorescence in situ hybridization (M-FISH; [@bb0100]) and array comparative genomic hybridization (aCGH; [@bb0095]) on both, pluripotent cell lines (iPSC and human embryonal stem cells = ESC) and their neuroprogenitor cell (NPC) derivatives; i.e. genomic abnormalities and variants may indeed appear as a result of in vitro differentiation.

2. Material and methods {#s0010}
=======================

2.1. Pluripotent stem cells (iPSC and ESC) and derived NPC cells {#s0015}
----------------------------------------------------------------

Here two human pluripotent stem cell line (iPSC and ESC) and one corresponding neuroprogenitor cell line (NPC) derivative were studied: the different iPSC and hESC and their corresponding derived NPC were obtained from the National Laboratory of Stem Cell, in Rio de Janeiro, Brazil. These cell lines were developed from a normal individual (ESC) and from a schizophrenic patient (iPSC). Those cells lines were established following standard procedures and are described in [@bb0035] (ESC) and [@bb0085] (iPSC).

2.2. Cytogenetics and molecular cytogenetics {#s0020}
--------------------------------------------

Cultured cells were prepared according to cytogenetic standard protocols. Chromosome suspensions were dropped onto slides as described in [@bb0010]. M-FISH was done using homemade whole chromosome painting probes according to [@bb0130]. 100--200 metaphases were acquired per case by a fluorescence microscope (Axioplan 2, Zeiss, Germany) with a PCO VC45 CCD camera (PCO, Kehl, Germany) using isis-software (MetaSystems, Altlussheim, Germany) for evaluation. Between 17 and 39 metaphases were evaluable and included into the results.

2.3. Array comparative genomic hybridization {#s0025}
--------------------------------------------

aCGH was performed using an Agilent Platform with a 180k chip according to manufacturer\'s protocol (Agilent Technologies, Santa Clara, CA, USA). Experiments were conducted using a gender-matched genomic DNA pool as reference. The quality of the experiment was evaluated with the QC metric provided by the CGH analysis software (CGH Analytics 3.5.14, Agilent Technologies). Data were analyzed using two different software packages (Blue Genome-Blue Fuse and Agilent) to determine the statistical validity of the findings.

3. Results {#s0030}
==========

All four cell lines could be analyzed by array-CGH. For M-FISH analysis only ESC (pluripotent cell line from normal male) did not yield any usable metaphase spreads.

3.1. M-FISH results {#s0035}
-------------------

M-FISH analysis revealed a high degree of chromosomal instability in the preparations of the pluripotent cells and their derivatives. Of the acquired metaphases (100--200/line), only a subset was suitable for detailed analyses due to clumsiness, and a significant incidence of single cell aberrations was found in those.

The original iPSC line showed a normal 46,XX\[cp17\] karyotype with no structural chromosomal aberrations as detected by M-FISH and inverted DAPI-banding. Non-clonal chromosome losses were detected in 11 of the 17 metaphases ([Table 1](#t0005){ref-type="table"}). As summarized in [Table 2](#t0010){ref-type="table"}, the NPC derived from iPSC had a karyotype of 46,XX\[cp39\], as well. M-FISH and inverted DAPI-banding revealed no structural chromosomal aberrations here, as in the original cell line.

As mentioned above, no metaphase spreads were available for FISH analysis for the induced pluripotent cell line ESC. However, according to the analysis of its derived cell line iPS3-derived NPC2, a normal karyotype should be present most likely in the original source. In contrast, the ESC-derived NPC had a 47,XY,+20\[cp10\]/46,XY\[cp13\] karyotype without structural chromosomal aberrations ([Fig. 1](#f0005){ref-type="fig"}). A description of the non-clonal chromosome losses detected in 14 of the 33 analyzed metaphases is presented in [Table 3](#t0015){ref-type="table"}.

Overall, M-FISH revealed the gain of chromosome 20 in a subset of one of the four studied cell lines. This trisomy 20 was present in \> 40% of the analyzed dividing cells \[(47,XY,+20\[10\]/46,XY\[13)\].

Interestingly, this cell clone was not detected in the aCGH test (see below).

3.2. aCGH results {#s0040}
-----------------

Overall fourteen different genomic regions exhibited genomic imbalances in the analyzed 4 cell lines. The details of found CNV are outlined in [Tables 4](#t0020){ref-type="table"} and [5](#t0025){ref-type="table"}.

4. Discussion {#s0045}
=============

Here 2 original cell lines and their corresponding NPC derivatives were studied by M-FISH and aCGH. It could be shown that the combination of molecular cytogenetics and aCGH leads to the detection of genetic imbalances on different levels of resolution.

M-FISH revealed normal karyotypes for the iPSC cell line and its derivative but a mosaic trisomy 20 in the NPC derived from ESC. Interestingly this was not detectable by aCGH. The latter can be due to the fact that the trisomy 20 was present in less than 50% of the cells. In our hands mosaics below 50% were not detectable yet using standard aCGH-software evaluation. No trisomy 20 was yet reported in any ESC or iPSC, only a 20q deletion was previously seen in one pluripotent stem cell line ([@bb0040]).

A general chromosomal instability in all studied lines ([@bb0090]) could be suggested according to the results presented in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}. However, this "instability" was most likely due to preparation artifacts as different, non-clonal chromosomes were lost in 54--64% of the evaluable 17 to 39 metaphases; the latter were selected from 100 to 200 metaphases being too clumsy and/or overspread.

aCGH proved the presence of CNVs in ESC and iPSC and their derived NPC. Our data support the view of two different origins for the structural variations as suggested by [@bb0070]: a) CNVs inherited from the original pluripotent cell source, either ESC or iPSC; and b) CNVs observed after the differentiation procedure and identified only in derived NPC. These observations indicate that differentiation ought to be considered in the same breadth as other types of manipulation (chiefly reprogramming and expansion of pluripotent cell lines) that are known to cause CNVs. The implications of this in the context of the potential development of cell therapies based on the differentiation of pluripotent cells cannot be underestimated ([@bb0110]).

Gains of copy numbers in 20q11.1--q11.21 as detected in one of the cell lines analyzed was already previously reported as a recurrent imbalance in stem cells ([@bb0105], [@bb0030], [@bb0075]). It was speculated, that this CNV leads to a growth advantage of the cells acquiring this CNV, as the gene BCL2L1 (OMIM \*[600039](600039)) having anti-apoptotic potential is included in this region ([@bb0055]). Interestingly in this study this amplification was present in the derivative NPC and not in the original iPSC, supporting the idea of acquisition of this CNV due to survival advantages under long term cultural conditions. CNVs classified as unique to IPSC, such as 1q31.3, 8q24.3 or 17q21.1 ([@bb0075]), were not identified in this study, which could be attributed to the small number of samples analyzed.

Overall, routine cytogenetic analysis is severely limited in its capacity to detect many of those changes, which may have clinical implications. The synergistic use of M-FISH and aCGH analyses would cover most genomic structural abnormalities at different levels.
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![M-FISH result of cell line NPC derived from ESC showing a karyotype 47,XY,+20. Trisomy 20 is highlighted by an arrowhead.](gr1){#f0005}

###### 

M-FISH results by chromosome for cell line iPSC.

  Chromosome                                         1               2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   X
  -------------------------------------------------- --------------- --- --- --- --- --- --- --- --- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---
  11 metaphases showed loss of chromosomes n times   0               0   0   1   0   0   1   0   1   1    0    0    1    0    0    0    1    2    2    4    1    1    0
  Composite karyotype                                46,XX\[cp17\]                                                                                                    

###### 

M-FISH results by chromosome for cell line NPC derived from iPSC.

  Chromosome                                         1               2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   X
  -------------------------------------------------- --------------- --- --- --- --- --- --- --- --- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---
  21 metaphases showed loss of chromosomes n times   6               3   0   0   2   3   2   4   1   4    3    3    4    2    2    0    3    4    3    4    1    6    3
  Composite karyotype                                46,XX\[cp39\]                                                                                                    

###### 

M-FISH results by chromosome for cell line NPC derived from ESC.

  Chromosome                                         1                                 2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   X
  -------------------------------------------------- --------------------------------- --- --- --- --- --- --- --- --- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---
  14 metaphases showed loss of chromosomes n times   1                                 0   1   0   1   3   3   1   3   3    0    5    2    1    2    5    1    2    2    4    0    4    0
  Composite karyotype                                47,XY,+20\[cp10\]/46,XY\[cp13\]                                                                                                    

###### 

aCGH results of ESC cell line and its NPC derivative obtained from a healthy subject.

  Chromosome       Cytoband       Begin         End           Gain \[MB\]   Loss \[MB\]
  ---------------- -------------- ------------- ------------- ------------- -------------
  *ESC*                                                                     
  1                q23.1          156,619,312   157,197,596   n.a.          0.578
  7                p22.3--p22.2   289,912       2,705,543     2.416         n.a.
  11               p15.5          357,497       2,002,404     1.645         n.a.
  17               q25.3          76,890,993    77,084,795    1.938         n.a.
  22               q11.21         18,471,124    19,063,627    0.593         n.a.
  22               q11.23         22,677,759    22,720,395    n.a.          0.653
                                                                            
  *NPC from ESC*                                                            
  1                q23.1          156,619,312   157,197,596   n.a.          0.578
  11               p15.5          357,497       2,002,404     1.645         n.a.
  15               q11.2          19,382,327    20,060,261    n.a.          0.678

###### 

aCGH results of iPSC cell line and its NPC derivative obtained from a schizophrenic subject.

  Chromosome        Cytoband        Begin         End           Gain \[MB\]   Loss \[MB\]
  ----------------- --------------- ------------- ------------- ------------- -------------
  *iPSC*                                                                      
  5                 q23.1           118,913,710   118,980,301   n.a.          0.067
  6                 q22.1           116,871,473   116,981,694   n.a.          0.110
  14                q32.32          102,446,974   102,499,423   0.052         n.a.
                                                                              
  *NPC from iPSC*                                                             
  7                 p22.3-p22.2     289,912       2,705,543     2.416         n.a.
  14                q32.32          102,446,974   102,499,423   0.052         n.a.
  17                q25.3           76,890,993    77,084,795    1.938         n.a.
  20                q11.1--q11.21   28,265,913    30,611,064    2.345         n.a.
